Class A Ordinary Shares, par value $0.0001 per share
- Symbol
- PCSC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Jul 20, 2026
Quarterly Report · 10-Q
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com.
Perceptive Capital Solutions Corp · 10-Q · Filed 2026-07-15